Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, for the month of April 2023. The report, dated April 19, 2023, discloses a significant corporate development regarding intellectual property rather than routine financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 16/076,026. This development strengthens the company's intellectual property portfolio.
Outlook, Risks, and Management Commentary
Management highlights that the resulting patent, once issued, will provide added intellectual property protection through at least 2036. The patent claims cover methods of using Allocetra in combination with chimeric antigen receptor (CAR) T-cell therapy to treat, ameliorate, or alleviate tumors. No specific financial guidance, risks, or contingencies were detailed in this specific filing text.
Key Facts for Investor Verification
- Patent application number 16/076,026 received a Notice of Allowance from the USPTO.
- The patent covers the use of Allocetra in combination with CAR T-cell therapy for tumor treatment.
- Intellectual property protection is expected to extend through at least 2036.
- The filing does not contain financial performance data for the period.